177 related articles for article (PubMed ID: 17923246)
1. P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors.
Connelly-Smith L; Pattinson J; Grundy M; Shang S; Seedhouse C; Russell N; Pallis M
Exp Hematol; 2007 Dec; 35(12):1793-800. PubMed ID: 17923246
[TBL] [Abstract][Full Text] [Related]
2. Macrophage 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in sitosterolemia: effects of increased cellular cholesterol and sitosterol concentrations.
Nguyen LB; Salen G; Shefer S; Tint GS; Ruiz F
Metabolism; 2001 Oct; 50(10):1224-9. PubMed ID: 11586498
[TBL] [Abstract][Full Text] [Related]
3. Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
al Rayyes O; Wallmark A; Florén CH
Hepatology; 1997 Apr; 25(4):991-4. PubMed ID: 9096609
[TBL] [Abstract][Full Text] [Related]
4. Pleiotropic effects of HMG-CoA reductase inhibitors.
Bocan TM
Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
[TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
6. Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin.
Suárez Y; Fernández C; Gómez-Coronado D; Ferruelo AJ; Dávalos A; Martínez-Botas J; Lasunción MA
Cardiovasc Res; 2004 Nov; 64(2):346-55. PubMed ID: 15485695
[TBL] [Abstract][Full Text] [Related]
7. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase activity is inhibited by cholesterol and up-regulated by sitosterol in sitosterolemic fibroblasts.
Honda A; Salen G; Honda M; Batta AK; Tint GS; Xu G; Chen TS; Tanaka N; Shefer S
J Lab Clin Med; 2000 Feb; 135(2):174-9. PubMed ID: 10695663
[TBL] [Abstract][Full Text] [Related]
8. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model.
Ugawa T; Kakuta H; Moritani H; Shikama H
Br J Pharmacol; 2002 Mar; 135(6):1572-8. PubMed ID: 11906972
[TBL] [Abstract][Full Text] [Related]
9. (TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.
Noriega V; Pennanen C; Sánchez MP; Chiong M; Llancaqueo M; Lavandero S; Prieto JC
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):211-5. PubMed ID: 19067673
[TBL] [Abstract][Full Text] [Related]
10. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
McAnally JA; Gupta J; Sodhani S; Bravo L; Mo H
Exp Biol Med (Maywood); 2007 Apr; 232(4):523-31. PubMed ID: 17392488
[TBL] [Abstract][Full Text] [Related]
11. Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells.
Yamasaki D; Nakamura T; Okamura N; Kokudai M; Inui N; Takeuchi K; Watanabe H; Hirai M; Okumura K; Sakaeda T
Eur J Pharm Sci; 2009 May; 37(2):126-32. PubMed ID: 19429419
[TBL] [Abstract][Full Text] [Related]
12. Reversal of P-glycoprotein-mediated multidrug resistance by cholesterol derived from low density lipoprotein in a vinblastine-resistant human lymphoblastic leukemia cell line.
Shu Y; Liu H
Biochem Cell Biol; 2007 Oct; 85(5):638-46. PubMed ID: 17901905
[TBL] [Abstract][Full Text] [Related]
13. Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.
Ibrahim S; Peggins J; Knapton A; Licht T; Aszalos A
Anticancer Res; 2001; 21(2A):847-56. PubMed ID: 11396174
[TBL] [Abstract][Full Text] [Related]
14. Interaction of the HMG-CoA reductase inhibitor lovastatin and nitric oxide in cardiomyocyte cell death.
Rabkin SW; Tsang MY
Pharmacology; 2008; 82(1):74-82. PubMed ID: 18504415
[TBL] [Abstract][Full Text] [Related]
15. Lovastatin inhibits oxidized low-density lipoprotein-induced plasminogen activator inhibitor and transforming growth factor-beta1 expression via a decrease in Ras/extracellular signal-regulated kinase activity in mesangial cells.
Song CY; Kim BC; Lee HS
Transl Res; 2008 Jan; 151(1):27-35. PubMed ID: 18061125
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin.
Massy ZA; Kim Y; Guijarro C; Kasiske BL; Keane WF; O'Donnell MP
Biochem Biophys Res Commun; 2000 Jan; 267(2):536-40. PubMed ID: 10631097
[TBL] [Abstract][Full Text] [Related]
17. High-dose lovastatin decreased basal prostacyclin production in cultured endothelial cells.
Zhou Q; Zhou Y; Kummerow FA
Prostaglandins Other Lipid Mediat; 2009 Jun; 89(1-2):1-7. PubMed ID: 19135546
[TBL] [Abstract][Full Text] [Related]
18. Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line.
Romiti N; Tramonti G; Chieli E
Toxicol Appl Pharmacol; 2002 Sep; 183(2):83-91. PubMed ID: 12387747
[TBL] [Abstract][Full Text] [Related]
19. Decreased ABCB1 mRNA expression induced by atorvastatin results from enhanced mRNA degradation in HepG2 cells.
Rodrigues AC; Curi R; Hirata MH; Hirata RD
Eur J Pharm Sci; 2009 Jun; 37(3-4):486-91. PubMed ID: 19394420
[TBL] [Abstract][Full Text] [Related]
20. [HMG-CoA reductase inhibitor for therapy of patients with hyperlipoproteinemia ].
Jingami H
Nihon Rinsho; 1994 Dec; 52(12):3271-8. PubMed ID: 7853722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
